Common side effects include: Gastrointestinal issues: Nausea, vomiting, constipation, and abdominal pain Injection site reactions: Redness, swelling, and pain Systemic issues: Fatigue, indigestion, heartburn, belching, and hair loss More severe side effects include: Thyroid problems: Medullary thyroid cancer and pancreatitis with severe, persistent abdominal pain Gallbladder problems with symptoms such as upper abdominal pain, fever, jaundice, or clay-colored stools Increased risk of hypoglycemia with symptoms such as dizziness, sweating, confusion, and shakiness Severe vomiting that leads to dehydration and kidney problems Mental health concerns such as depression and suicidal thoughts Vision changes from rapid changes in blood glucose levels Some patients should not use Zepbound, such as those who have or are at risk for medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Although the absolute difference in cancer incidence with GLP-1 receptor agonists compared with dipeptidyl peptidase-4 (DPP-4) inhibitors is small, the relative risk difference observed in the study could have an impact on a population level, lead author Lucas A
The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight
It helps reduce cravings, manage withdrawal symptoms, and create stability during treatment
